TCR2 Therapeutics

$28.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.71 (+6.46%) As of 5:24 PM UTC today

Why Robinhood?

You can buy or sell TCRR and other stocks, options, and ETFs commission-free!

About TCRR

TCR2 Therapeutics Inc. Common Stock, also called TCR2 Therapeutics, is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA. The listed name for TCRR is TCR2 Therapeutics Inc. Common Stock.

CEO
Garry E. Menzel
Employees
83
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
1.05B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
381.29K
High Today
$29.06
Low Today
$27.37
Open Price
$27.72
Volume
173.57K
52 Week High
$35.86
52 Week Low
$5.84

TCRR Earnings

-$0.67
-$0.45
-$0.22
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 30, Pre-Market

You May Also Like

REET
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure